Marco Ruggeri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7926530/publications.pdf

Version: 2024-02-01

15	2,653	12	14
papers	citations	h-index	g-index
15	15	15	2743
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113, 2386-2393.	1.4	2,128
2	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood, 2013, 121, 2596-2606.	1.4	179
3	The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis. Annals of Internal Medicine, 2003, 139, 470.	3.9	65
4	Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use. Stem Cell Research and Therapy, 2017, 8, 14.	5 . 5	49
5	A comparative prospective observational study of children and adults with immune thrombocytopenia: 2â€year followâ€up. American Journal of Hematology, 2018, 93, 751-759.	4.1	38
6	High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sources. Stem Cell Research and Therapy, 2018, 9, 10.	5 . 5	37
7	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 2018, 103, e392-e394.	3.5	31
8	Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. American Journal of Hematology, 2018, 93, 58-64.	4.1	31
9	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. Blood, 2021, 138, 571-583.	1.4	26
10	Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome. European Journal of Haematology, 2020, 105, 468-475.	2.2	21
11	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 2019, 8, 4089-4092.	2.8	16
12	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia Research, 2018, 69, 100-102.	0.8	13
13	Thrombotic and hemorrhagic complications in idiopathic erythrocytosis. American Journal of Hematology, 2017, 92, E639-E641.	4.1	11
14	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology, 2020, 95, E1-E3.	4.1	8
15	A flow cytometric assay for the quantification of MSC lysis by peripheral blood mononucleated cells. Heliyon, 2021, 7, e06036.	3.2	0